{"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"38"}],"units":"Participants"}],"groups":[{"description":"Phase I patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1\n* 10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"BG000","title":"Phase I"},{"description":"Phase II patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* 0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"BG001","title":"Phase II"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"36","upperLimit":"80","value":"60.5"},{"groupId":"BG001","lowerLimit":"42","upperLimit":"83","value":"68.5"},{"groupId":"BG002","lowerLimit":"36","upperLimit":"83","value":"62.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"17"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"21"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"38"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"All participants accrued to this study were analyzed for baseline characteristics"}